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EFFECT OF PHENOBARBITAL ON EXTRACELLULAR MATRIX PRODUCTION, 
CELL REPLICATION, AND TRANSFORMING GROWTH FACTOR-pl RECEPTOR 
PROFILE IN RAT DERMAL FIBROBLAST CULTURES. 
Rani K. Spudich, Sandra Casinghino, and Michael Centrella. Section of Plastic and 
Reconstructive Surgery, Department of Surgery, Yale University School of Medicine, 
New Haven, CT. 
Transforming growth factor-pi (TGF-P 1) enhances cell replication and extracellular 
matrix synthesis, and associates with distinct cell-surface binding sites in human fibroblast 
cultures. Phenobarbital therapy for seizure disorders has been shown to result in a 10% 
increase in incidence of connective tissue disorders in patients taking the drug, an effect 
that may be mediated in part by changes in local TGF-P 1 actions in dermal tissue. The 
purpose of our study was to evaluate whether phenobarbital stimulates extracellular matrix 
production via TGF-pi-mediated effects in fibroblasts, thus directly playing a role in 
connective tissue disorder pathogenesis. DNA and collagen synthesis were measured by 
metabolic labeling techniques, while TGF-P receptors were examined by polyacrylamide 
gel electrophoresis coupled either with1251-ligand binding, or specific anti-receptor 
antibody probing. Preexposure of rat dermal fibroblast cultures derived from fetal rat 
scalp to 30 p.M phenobarbital did not alter basal DNA or collagen synthesis, nor did it 
affect the stimulatory effects of TGF-P 1 on these parameters. Binding studies revealed 
that phenobarbital caused decreased TGF-P 1 binding within Mx 250,000 (betaglycan), Mr 
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85,000 (type II), and Mr 65,000 (type I) TGF-(3-binding complexes. In addition to 
decreased binding, total protein amounts of TGF-P receptor types I and II also decreased 
after exposure to 30 pM phenobarbital. In order for phenobarbital to cause a pathologic 
increase in matrix deposition, we had expected to see an increase in TGF-P 1 binding to 
the cell-signaling receptors (types I and II), and perhaps a concurrent decrease in 
betaglycan which functions as a storage site for the TGF-P 1 molecule. Our present data 
therefore suggests that phenobarbital does not directly modulate TGF-P 1-stimulation of 
extracellular matrix protein synthesis or cell proliferation in rat dermal fibroblasts. 
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Transforming growth factor-P (TGF-J3) is one of a family of molecules which 
regulates tissue development, cell physiology and many aspects of the immunological 
response. The continued investigation of the action of this growth factor and others 
contributes to our understanding of both normal cell function, and dysregulation of 
function in disease states. 
Initially characterized by Roberts and Sporn in 1981, TGF-P was so named 
because its addition enabled normal rat fibroblasts to proliferate in soft agar - a feat 
previously accomplished by only virus-infected (“transformed”) cells. Since the time of 
those studies, TGF-P has been found to have varied, and interestingly often opposing 
effects on cell growth and differentiation, embryogenesis, immune regulation, 
inflammation, and tissue repair. Overviews of the recent literature about TGF-P are 
presented in reviews by Border and Noble (1995), and by Okragly et al. The molecule’s 
action appears to be both autocrine and paracrine, and some of its specific effects are to 
modulate bone formation, angiogenesis, hematopoesis, cell cycle progression, cell 
migration, and extracellular matrix production. The molecule has been isolated from many 
different cell types, including platelets, placenta, kidney (Roberts et al., 1983), and bone 
(Centrella & Canalis, 1985), suggesting its fundamental importance in cell physiology. 
I 
This ability to modulate cell growth in many ways groups TGF-P with other 
described cytokines such as epidermal growth factor (EGF), platelet-derived growth 
factor (PDGF), fibroblast growth factor (FGF), tumor necrosis factor (TNF), interleukins 
and colony stimulating factors. All of these cytokines function to maintain homeostasis 
within the cells of the body’s tissues and in the surrounding extracellular matrix. This 
ability is all the more remarkable since the same cytokine can have stimulatory or 
inhibitory effects upon a given cell type depending upon such factors as the stage of the 
cell cycle, and the presence or absence of other cytokines. In general however, TGF-P 
appears to be stimulatory for mesenchymal cells and inhibitory for epithelial cells. 
TGF-P is a regulatory protein belonging to a “superfamily” of structurally related 
polypeptide regulatory factors. This superfamily includes five TGF-P isoforms, TGF-P 1 
to TGF-P5, along with the activins, inhibins, and bone morphogenetic proteins (BMPs). 
Of the TGF-P isoforms, only TGF-P 1, 2, and 3 are mammalian (TGF-P4 has been 
described in birds and TGF-P5 in amphibians). TGF-P 1 is the best characterized and most 
abundant isoform in mammals. Its ubiquitous nature is evidenced by the fact that its 
amino acid structure is conserved across species, being identical in chickens, cows, pigs, 
monkeys and humans, and differing in the mouse by only one residue. 
TGF-P 1 is secreted in a latent, or inactive form, and is modified for active receptor 
binding. The active form of TGF-P 1 is a 25 kDa protein dimer composed of two identical 
12.5 kDa subunits joined by disulfide linkages. The molecule is translated as a 390 amino 

3 
acid propeptide which becomes cleaved by proteases to create two fragments: a C- 
terminal peptide of 112 amino acids and a “latency-associated peptide,” 278 amino acids 
in length. The active dimer mentioned above is formed by the disulfide bonding of two C- 
terminal peptides - however, the latency-associated peptide immediately noncovalently 
binds the dimer to form the 100 kDa “latent TGF-P 1 complex.” Yet another factor, the 
“latent TGF-P binding protein” may also attach. It is hypothesized that latent TGF-pi is 
stored on the cell surface or in the neighboring extracellular matrix until it is needed. 
Activation of the cytokine occurs by removal of the latency-associated peptide. The 
mechanism by which this occurs in vivo is not well understood, but likely involves 
protease action. 
The many effects of the TGF-P 1 molecule are realized via a cell-signaling cascade 
initiated at the level of cell-surface receptors. Nine proteins have been recognized to bind 
TGF-P 1 at or near the cell membrane (reviewed by Massague, 1992). Three of these are 
most abundant: two are true transmembrane receptors, known as receptor types I and II, 
while the third is an extracellular proteoglycan somewhat misleadingly known as receptor 
type III. The current evidence, however, suggests that the type III “receptor” is not itself 
involved in signal-transduction, therefore, it is perhaps more appropriately known as 
“betaglycan.” The type I and II receptors have molecular weights of 53 kDa and 70 kDa 
respectively, while betaglycan is largest at 200-400 kDa. 
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Understanding the TGF-P 1 signal transduction pathway is a current topic of 
research. To date, the data has suggested that this pathway may differ among cell types. 
One body of knowledge suggests that both receptor types I and II, shown to be serine- 
threonine kinases, are necessary for signal transduction (reviewed by Massague et al., 
1994; Miyazono et al., 1994). This model supports the idea that the TGF-P molecule first 
binds the type II receptor, forming a complex that “recruits” the type I receptor. In this 
model, the type I receptor becomes phosphorylated by the constitutively active protein 
kinase domain of type II, thus initiating the signaling cascade (Wrana et al., 1992; Wrana 
et al., 1994). In the chemically mutated mink lung epithelial cells where the model was 
first formulated, cell responsiveness to TGF-P is lost when only one of the two receptors 
is in existence (Attisano et al., 1993). In other words, the evidence from these studies 
suggests a constant ratio between receptor types I and II is necessary for cell signaling to 
occur. In our laboratory, however, research by Michael Centrella and Thomas McCarthy 
has shown that in several cell culture models the type I receptor may bind TGF-P 1 and 
propagate the signaling process independently of type II sites, depending upon the stage of 
differentiation of the cell. If the type I receptor truly functions “downstream” of type II in 
the signaling process (discussed further below), Centrella and McCarthy postulate that it 
may become activated via phosphorylation by other cellular kinases as yet undefined, and 
thus independently initiate the cell signal. 
Because it is not required for signal transduction in some cell types, the role of 
betaglycan (type III receptor) remains undefined. Its core protein contains 853 amino 
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acids, and at least half of its mass derives from glycosyl side chains. The proteoglycan 
may be found in a soluble, extracellular form, or alternatively may be anchored in the cell 
membrane. The membrane-bound form has a transmembrane segment and short 
intracellular region, but is primarily made up of a large extracellular domain (Lopez- 
Casillas et al., 1991). It has been hypothesized that in its soluble form, betaglycan acts as 
a storage vehicle for TGF-Pl, keeping the growth factor from interacting with the 
signaling receptors. It has also been proposed that a membrane-bound form of betaglycan 
is involved in presenting TGF-pi to the receptor types I and II, thus assisting the signaling 
cascade (Lopez-Casillas et al., 1993). 
The specifics of the ligand-receptor binding leading to physiologic response within 
the cell are only just becoming elucidated. Quite recently a new gene family named “Mad” 
has been identified as playing a role in the TGF-(3 signal transduction pathway (reviewed 
by Derynck & Zhang, 1996; Massague, 1996). “Mad” was described in Drosophila, 
where its function was found to be required for activity of DPP (Decapentaplegic), a TGF- 
(3 analogue. DPP initiates its signal via a similar interaction of a Type II receptor (named 
“Punt” in Drosophila) with a Type I receptor (two variations being “Thick veins” and 
“Saxophone”) as previously described for TGF-P1. Such findings as that the 
overexpression of Mad partially rescues DPP deficiencies have led researchers to conclude 
that Mad functions downstream of the DPP Type I receptor. The products of the Mad 
genes are proteins of ~450 amino acids with highly conserved N-terminal and C-terminal 
domains, and a variable proline-rich intervening region. In response to receptors binding 
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ligands, it appears that Mads undergo serine phosphorylation, and accumulate in the cell 
nucleus. It is hypothesized that Mads may then interact with specific response elements in 
target genes, thereby activating their transcription. Mad homologues have been identified 
in other organisms, including the human (Smadl). It has therefore been suggested that, in 
humans, different TGF-P family members may signal through different Mad isoforms. 
Further, the same TGF-P molecule may effect different biological responses, mediated by 
different Mads, or different amounts of Mad transcript. 
So, what is the end result of this intricate cascade? Previously mentioned is that 
TGF-P 1 has the capacity to both stimulate and inhibit cell division and proliferation. Not 
surprisingly, research over the past five years has begun to elucidate that multiple 
interactive mechanisms exist by which TGF-P 1 ultimately affects cell cycle kinetics. While 
the complex details of these pathways are in the process of being characterized, some of 
the fundamental concepts follow, as reviewed by Saltis, 1996: In mammalian cells, the G1 
phase of the cell cycle is regulated by a family of cyclin-dependent kinases (primarily 
CDK2, 4, and 6) as well as by specific CDK activators, the cyclins (mainly cyclin D and 
E). One of the most important substrates of G1 CDKs in regulating the cell cycle is the 
retinoblastoma gene product, “pRb.” pRb, if not phosphorylated, inhibits cell cycle 
progression, while phosphorylation reverses that inhibition. It has been demonstrated that 
in cells where TGF-P 1 stimulates cell division (mesenchymal cells), retinoblastoma protein 
is phosphorylated and releases a transcription factor “E2F.” E2F is transported to the 
nucleus where it increases the transcription of genes that prepare the cell to enter the S 
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phase. In cell types where growth is inhibited by TGF-P 1 (epithelial, endothelial, and 
hematopoietic cells), the activation of the CDK2-cyclin E complex by CDK4-cyclin D is 
inhibited, and pRb remains unphosphorylated. E2F therefore remains bound and 
unavailable for initiation of transcription, thus blocking cell division. 
Once again, the overriding message from all of this is that the effects of TGF-P 1 
on the physiologic functions of many cell types are multiple and varied, and may be 
explained by alterations in production, secretion, and subsequent activation of latent TGF- 
P, by changes in TGF-P receptor expression, and by alterations in post-receptor signaling. 
In addition to understanding the role of TGF-P in maintaining healthy tissues, the 
investigation of dysregulation of TGF-P actions may be the key to specific pathologic 
processes in humans. Already, researchers have postulated that dysregulation of TGF-P is 
involved with the development of congenital defects, carcinogenesis, and chronic 
inflammatory and fibrotic diseases. 
Both research projects with which I was involved during medical school addressed 
the involvement of TGF-P 1 in the pathogenesis of fibrotic diseases. In one project, the 
disease process of interest included connective tissue disorders in general, exemplified by 
Dupuytren’s contracture of the hand, while the second project concerned the process of 
vascular restenosis (Yang, Spudich et. al, 1995). What follows will provide an overview 
of the first of these two diseases and the questions addressed in my research on this topic. 
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The most extensively studied effect of TGF-pi is its stimulatory effect on 
extracellular matrix proteins. This occurs by multiple pathways: first, TGF-pi enhances 
collagen gene expression in a number of cell types including fibroblasts and osteoblasts. 
Simultaneously, TGF-pi is known to inhibit the production of proteases that degrade the 
matrix, and moreover, it increases the levels of protease inhibitors (Edwards et al., 1987; 
Laiho et al., 1986). Further studies have demonstrated that TGF-pi upregulates the 
expression of integrin receptors, thereby causing cells to more tightly adhere to the matrix. 
Collectively, these actions result in increased deposition and accumulation of ECM 
surrounding cells in a given tissue. 
In the physiologic wound-healing process, the laying down of new ECM is 
fundamental to scar development. One can imagine, however, that dysregulation of this 
process resulting in excessive matrix secretion could cause scar hypertrophy and/or severe 
tissue contraction and fibrosis. Such a process has already been described in the 
pathogenesis of glomerulosclerosis and tubulointerstitial fibrosis in the kidney, where 
excess ECM accumulates in the glomeruli and tubules, destroying the organ’s filtration 
capacity. 
Dupuytren’s contracture, formally called nodular palmar fibromatosis, is a 
condition first described 150 years ago as involving apparent fibrotic changes in the dermis 
and palmar fascia of the hand. The disease predominantly affects elderly male Caucasians, 
may have a hereditary component, and is strongly associated with diabetes, alcoholism, 
I 
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cigarette smoking and HIV infection. It has since been postulated that increased synthesis 
of ECM, along with an acquisition by fibroblasts of a smooth muscle-like phenotype, are 
responsible for the resultant contracture and compromise in utility of the affected hand. 
Studies to date have demonstrated an increased total number of fibroblasts in Dupuytren’s 
contracture (six- to forty-fold), a more disorganized pattern of collagen fibrils, and the 
fibroblasts to be clustered about narrowed microvessels. Finally, while type I collagen is 
predominant in the ECM of both normal and diseased palmar fascia, the ratio of type III to 
type I collagen is increased in Dupuytren’s contracture. Murrell et al. (1991) determined 
that this ratio is not due to any intrinsic abnormality in collagen production by 
Dupuytren’s cells; rather, the increased fibroblast density appears to inhibit type I collagen 
specifically which would explain the altered type III to type I ratio. 
Baird et al. (1993) examined tissue samples from patients with and without 
Dupuytren’s contracture, using reverse transcriptase/PCR to compare the relative amounts 
of various peptide regulatory factors expressed. These investigators found TGF-P mRNA 
in significantly higher amounts in the diseased tissue as compared to healthy tissue. Alioto 
et al. (1994) cultured cells from both normal palmar and Dupuytren’s fascia, added TGF- 
P, and compared the cytokine’s effect on proliferation rate and collagen production 
between the two cell types. They concluded that TGF-P is a potent stimulator of collagen 
synthesis in both cells types, but not mitogenic for fibroblasts that are either presently 
growing or not growth arrested, unlike the growth factors FGF and PDGF. They also 
noted that at baseline, Dupuytren’s cells are more metabolically active and more sensitive 
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to all the growth factors they tested. These results are consistent with the hypothesis that 
TGF-(3 may contribute to the pathogenesis of this disease process. 
Further, Kloen et al. (1995) found the presence of all three TGF-(3 receptor types 
on primary cultures of Dupuytren cells and normal dermal fibroblasts. Interestingly, their 
findings showed the type I receptor to be expressed significantly less, or, to have a lower 
affinity for TGF-|31, than the type II receptor in Dupuytren cultures. In comparison, there 
was virtually no difference between binding of TGF-(31 to these two receptor types in 
normal fibroblasts. In contrast to Alioto’s results, Kloen’s group found that addition of 
TGF-pi did stimulate DNA synthesis in Dupuytren cells. However, in concurrence with 
the previous results, there was little mitogenic response to TGF-(31 in normal fibroblasts. 
Unexpectedly, Kloen also found that normal fibroblasts produced more TGF-|3 than 
diseased cells. 
Also fascinating is the study by Tomasek and Rayan (1995) demonstrating greater 
expression of alpha-smooth muscle actin in Dupuytren’s fibroblasts than in control tissue. 
Further, using a collagen lattice contraction assay, they found a positive correlation 
between this increased actin expression and an increase in contractile force in Dupuytren’s 
cells. This data suggests that Dupuytren’s fibroblasts can acquire something of a smooth 
muscle-like phenotype which may contribute to the contractility of the surrounding tissue. 

As previously stated, Dupuytren’s contracture is associated with a number of 
clinical predisposing factors such as diabetes, smoking, alcoholism, and HIV infection. 
The actual mechanism by which these risk factors may cause palmar fibrosis is unclear, but 
some studies have hypothesized the involvement of free radicals which I will not discuss 
here. In 1989, Mattson et al. coordinated a prospective study among Veterans 
Administration patients to evaluate previously reported retrospective associations between 
connective tissue disorders and yet another factor, antiepileptic medications. In this study, 
10 (6%) of 178 patients who were treated for six months or more with a single barbiturate 
(phenobarbital or primidone) developed connective tissue disorders, with 7 of the 10 
problems occurring within the first year of treatment. This data proved to be of statistical 
significance as compared to findings from 228 patients receiving other drugs. The 
connective tissue disorders developed included Dupuytren’s contractures, frozen shoulder, 
Peyronie’s disease (penile fibromatosis), and generalized joint pain. 
Given the data from Mattson’s study and the understood stimulatory effect of 
TGF-(31 on ECM production, my principal investigator. Dr. Michael Centrella, and I set 
out to answer a few logical questions. First, do barbiturates specifically stimulate ECM 
production in dermal fibroblasts? Second, do barbiturates stimulate fibroblast 
proliferation? Third, if the answer is “yes” to either of these questions, is TGF-pi a 
mediator of these outcomes? And fourth, if TGF-PI is involved, is the receptor profile - 
that is, the ratio between TGF-P receptor types I, II, and betaglycan - modulated as part 
of the cell signaling mechanism? 
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To address these questions, we decided to model our study after another 
completed in our laboratory where Centrella et al. (1991) investigated the effect of 
glucocorticoid on bone matrix collagen synthesis. The premise of this prior study was that 
steroid-induced bone loss may be mediated in part by changes in local TGF-P actions in 
skeletal tissue. By pre-exposing osteoblast-enriched cell cultures to cortisol they 
demonstrated a 40-50% reduction of the stimulatory effects of TGF-P 1 on DNA and 
collagen synthesis. Additional binding studies showed that exposure to cortisol resulted in 
decreased TGF-P 1 binding to type I and type II receptor complexes, whereas binding to 
betaglycan increased, suggesting increased extracellular storage of TGF-P 1. The authors 
concluded that glucocorticoids can decrease the anabolic effects of TGF-P 1 in bone, in 
part by a redistribution of its binding toward ECM storage sites. 
Similarly, for the current experiment we chose to use an in vitro cell culture model 
of rat dermal fibroblasts (readily available and used for other experiments in our 
laboratory). Our first aim was to determine whether phenobarbital (one of the barbiturates 
from Mattson’s study) exposure causes an increase in the biological effects of TGF-pi in 
these cells. We planned to assess overall fibroblast proliferation by measuring 
[ H]thymidine incorporation as a gauge of DNA synthesis. Relative collagen and non¬ 
collagen protein synthesis was to be measured by assaying [3H]proline incorporation and 
differential sensitivity to digestion with purified collagenase. Our second aim was to 
determine what effect phenobarbital has on TGF-P receptor expression in rat dermal 
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fibroblasts. Specifically, we wanted to determine whether phenobarbital exposure alters 
the levels of TGF-(31 binding to type I and type II receptors and betaglycan. TGF-(3 
receptors were to be quantified through binding studies using 12:,I-TGF-pi, and by 
Western blot staining with specific antisera. This study will help clarify the relationship, if 
any exists, between the dynamic maintenance of extracellular matrix and barbiturate 
exposure in dermal tissue. 
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MATERIALS & METHODS 
All experiments were conducted by myself, with the exception of the initial dermal 
fibroblast cell cultures. In our laboratory, cell cultures have been routinely prepared by 
one individual to maintain a consistent model. Therefore I used cell cultures prepared by 
Sandra Casinghino who has done so for more than 10 years. 
Cell Culture and Treatments 
Primary dermal fibroblast cultures were prepared from scalp skin, taken directly above the 
parietal bones of 22-day-old rat fetuses [stock designation Crl:CD(SD)BR, derived from 
Sprague-Dawley rats, Charles River Breeding Laboratories, Raleigh, NC], 
Dermal/epidermal tissue from 10 rat fetuses was removed and digested together at 37°C 
for 1 hour with 1000 units (10 ml) collagenase (Type 2, Worthington Biochemical 
Company). Undigested tissue was discarded, and isolated cells were pelleted by 
centrifugation for 4 minutes at 4000 rpm. The supernatant, containing the collagenase, 
was discarded, and cells were resuspended in Dulbecco’s modified Eagle’s medium 
containing 20 mM W2-hydroxyethylpiperazine-Ar’-2-ethanesulfonic acid (HEPES) buffer 
(pH 7.2), 100 pg of ascorbic acid per ml, penicillin and streptomycin, and 10% fetal 
bovine serum (FBS). Cells were plated in 75cm2 flasks and incubated at 37°C in a 
humidified incubator with 95% 02-5% CO2. When cultures reached confluence the cells 
were trypsinized and plated into 6-, 12-, or 24-well plates for experiments. For all studies, 
cells from passage 1 were used. Prior to each treatment, cells were grown to confluence 
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in medium containing 10% FBS and were then re-fed identical medium lacking FBS 
(“serum-free medium”). Twenty-four hours later, they were re-fed serum-free medium 
containing various agents for the times indicated for each experiment. 
Test Agents 
Cell culture reagents were obtained from GIBCO (Grand Island, NY). 
The TGF-pi used in these studies was a recombinant simian preparation identical in amino 
acid sequence to human TGF-pi (examined in collaboration with Bristol-Myers Squibb, 
Inc., Seattle, WA), which exhibits binding and biological characteristics indistinguishable 
from our lab’s earlier studies with other native or recombinant preparations. TGF-pi was 
dissolved in 0.05 M HC1 containing 4 mg of bovine serum albumin (BSA) per ml to obtain 
a concentration of 8 nM and was stored at 4°C. 
Cortisol (hydrocortisone [Sigma]) was dissolved in 95% ethanol to obtain a concentration 
of 10 mM and was diluted as needed in serum-free culture medium prior to use. 
Phenobarbital was dissolved in 12.6% warm water/87.3% DMEM to obtain a 
concentration of 3 mM and was diluted as needed in serum-free culture medium prior to 
use. 
Cell Replication 
Vehicle or test agent was added in serum-free medium, and cultures were incubated for 
additional intervals, designated for each figure. Effects on DNA synthesis were measured 
by pulse-labeling cultures with [/we//7>>/-3FI]thymidine (5 pCi/ml, 80 Ci/mmol; Dupont 
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NEN) during the last two hours of treatment, f H]thymidine incorporation into DNA was 
determined by cell lysis with 0.1M sodium dodecyl sulfate-0. IN sodium hydroxide, 
collection of the material precipitated by 10% trichloroacetic acid, and scintillation 
counting. 
Protein Synthesis 
Effects on collagen and non-collagen protein (NCP) synthesis were measured by pulse¬ 
labeling cultures with 12.5 pCi of [2,3-'H]proline (2.5 Ci/mmol; Dupont NEN, Boston, 
Mass.) per ml for the last two hours of treatment. Cells were lysed by freeze-thawing; 
lysates were collected in 0.5% Triton X-100 (Sigma Chemical Co., St. Louis, MO), 
precipitated with 10% trichloroacetic acid, and chilled; and the acid-precipitable material 
was collected by centrifugation. The precipitates were acetone extracted, dried, re¬ 
solubilized in 0.5M acetic acid, and neutralized with 0.5M sodium hydroxide. (/H]proline 
incorporation into collagenase-digestible protein (CDP) and NCP was measured by using 
collagenase purified free of nonspecific protease activity (Worthington Biochemicals) and 
is shown as the total amount of [?H]proline incorporated per culture. Percent collagen 
synthesis (PCS) was calculated after correcting for the relative abundance of proline in 
CDP and NCP. 
Binding Studies 
TGF-pi was radioiodinated with chloramine T to a specific gravity of 4000-4500 
Ci/mmol. Radioligand was separated from unincorporated 125I by gel filtration on 
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Sephadex G-50 in a solution of 0.1 M acetic acid and 4 mg/ml bovine serum albumin 
(BSA). Binding was examined by incubation with serum-free medium containing 4 mg/ml 
BSA (binding medium) and 50-150 pM 125I-TGF-P1 for three hours at 4°C. To visualize 
TGF-P binding complexes, cultures were rinsed with chilled binding medium, cross-linked 
with 0.2 mM disuccinimidyl suberate (Pierce Chemical Co., Rockford, IL), and extracted 
in a phosphate buffered saline solution containing 1% Triton X-100. A standard amount 
of protein (100 ng) was loaded in each lane, fractionated by electrophoresis on 
polyacrylamide gels (5-10%), and examined by autoradiography. Densitometry was 
assessed using a ScanMan densitometer and SigmaGel® (Jandel, San Rafael, CA). 
Receptor Analysis 
For Western blot analysis (total receptor protein quantification), cultures were extracted in 
a phosphate buffered saline solution containing 1% Triton X-100, 0.02 mM calcium 
chloride and 0.2 mM magnesium chloride, and extracts were fractionated by 
polyacrylamide gel electrophoresis (5-10%) with 100 ng protein loaded in each lane. 
Extracts were then blotted onto Immobilon P membranes (Millipore Corp ), blocked with 
a 5% (w/v) de-fatted milk solution, probed with anti-TGF-PR specific antibody 
preparations (Santa Cruz Biotechnology, Inc.), and visualized with SuperSignal™ Western 




The purpose of our studies was to assess the affect of the barbiturate phenobarbital on rat 
dermal fibroblasts in vitro. The parameters we chose to evaluate after phenobarbital 
exposure included DNA synthesis as a measure of cell proliferation, collagen synthesis as a 
measure of overall extracellular matrix production, and the quantity of and TGF-P 1 
binding to the three TGF-P receptor subtypes commonly found on mammalian cells. 
DNA Synthesis 
Our first objective was to determine whether phenobarbital affects DNA synthesis in these 
fibroblasts. As previously reported (Centrella et al., 1991), treatment of fetal rat 
osteoblast cultures with TGF-P 1 for 23 hours induces a dose-related biphasic stimulatory 
effect on DNA synthesis, with peak stimulation occuring at 1 ng/ml TGF-P 1. Therefore, 
in order to determine the TGF-P 1 dose which maximally stimulates our rat dermal 
fibroblasts, we treated our cell cultures for 24 hours with TGF-P 1 concentrations varying 
from 0.03 to 3.0 ng/ml, subsequently evaluating each treatment group for ['HJthymidine 
incorporation. We found maximal stimulation of DNA synthesis at a TGF-P 1 
concentration of 0.1 ng/ml in our cells, at which concentration mitogenesis was enhanced 
about 2.5-fold (Fig. 1). 
Also previously reported in osteoblasts (Centrella et al., 1991) is the finding that 100 nM 
cortisol reduces basal DNA synthesis rates and suppresses the known mitogenic effect of 

TGF-Pl at 1 ng/ml and lower concentrations. Exposure of our fibroblasts to this same 
concentration of cortisol produced similar outcomes: basal DNA synthesis rates were 
reduced as compared to untreated cells, and the observed mitogenic effect of 0.1 ng/ml 
TGF-Pl was suppressed by 85% (Fig. 2). No notable effects of 30 to 300 pM 
phenobarbital were observed on basal DNA synthesis rates, and TGF-Pl appears to 
stimulate mitogenesis to the same extent with or without these concentrations of 30 to 300 
pM phenobarbital. Both basal and TGF-pi-stimulated DNA synthesis were inhibited by 3 
mM phenobarbital by 25 - 30%. 
Collagen Synthesis 
Our second objective was to determine whether phenobarbital affects collagen synthesis in 
rat dermal fibroblasts. TGF-Pl is a well-known enhancer of type I collagen synthesis in 
fibroblasts (see Border & Noble, 1995). As previously described for osteoblasts 
(Centrella et al., 1991), collagen synthesis is enhanced by TGF-pi concentrations ranging 
from 12 to 1200 pM in a steadily increasing fashion with maximal effect near 120 pM and 
with amount of synthesis remaining fairly constant at higher doses TGF-Pl. Given the 
similarities between the TGF-Pl standard curves for fetal rat osteoblasts and dermal 
fibroblasts with respect to DNA synthesis, and the reliable stimulation of collagen 
synthesis in osteoblasts at all tested TGF-pi concentrations, we did not carry out our own 
dose-response curve with respect to collagen synthesis. However, in separate 
experiments, when TGF-pi was tested at 2.5 ng/ml, collagen synthesis increased by 50%, 
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while 10 ng/ml produced a 2.0 to 2.5-fold increase. The results reported here reflect those 
studies carried out at a concentration of 10 ng/ml. 
At baseline, 10 ng/ml TGF-Pl increased collagen-digestible-protein (CDP) synthesis 
approximately twofold (Fig. 3). 100 nM cortisol reduced basal CDP synthesis and 
decreased the stimulatory influence of TGF-(31 by about 66%. Phenobarbital exposure 
resulted in minimal variation of CDP synthesis both without and with TGF-Pl treatment 
as compared to untreated samples at phenobarbital concentrations of 3 to 300 pM. At 3 
mM phenobarbital, it inhibited both basal and TGF-(31 -stimulated collagen synthesis. 
Phenobarbital similarly had no apparent affect on non-collagen protein (NCP) synthesis in 
our cells except for at the highest dose of 3mM, where it was inhibitory as for the CDP 
samples (Fig. 4). 100 mM cortisol only minimally inhibited basal NCP synthesis, but 
appeared to cause a 10 to 50% inhibition of the stimulatory effect of 10 ng/ml TGF-pi in 
two independent studies. However, the changes in CDP and NCP were not as evident in 
experiments carried out with 2.5 ng/ml TGF-Pl. 
Receptor Assays 
Our third objective was to investigate the response of TGF-P receptor types I, II, and III 
(betaglycan) to phenobarbital exposure. Our approach was two-fold: after phenobarbital 
treatment, we first examined the extent of ligand binding to each receptor subtype, and 
second, the total amounts of each receptor protein in our cells. Ligand binding was 
measured using 125I-TGF-pi, chemical cross-linking, and polyacrylamide gel 
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electrophoresis as described in Materials and Methods. Individual absolute receptor 
amounts were quantified using polyacrylamide gel electrophoresis and by probing with 
antibodies specific for each receptor subtype as described in Materials and Methods. 
Quantification of bands detected by autoradiography was carried out by densitometric 
analysis of intensity times total area. Densitometry for all bands from a given experiment 
was carried out at one sitting, so that the readings should accurately represent relative 
amounts of I25I-TGF-(31 or antibody binding to phenobarbital-exposed cells versus 
control cells. 
As in previous studies (Kloen et al. 1995), 125I-TGF-|31 binding was detected primarily 
within complexes migrating at molecular weights of 65 kDa, 73 kDa, and >200 kDa, 
analogous to the types I, II, and betaglycan binding sites, respectively. For antibody 
binding, migration was at 53 kDa, 70 kDa, and >200 kDa due to the absence of 
complexed ligand. Treatment with 100 nM cortisol for 24 h prior to the addition of 125I- 
TGF-Pl resulted in an 86% reduction in labeling of the type I receptor, a 42% reduction 
in binding to the type II receptor, and a 33% reduction in binding to betaglycan (Figs. 5- 
7). 24-h treatment with 30 pM phenobarbital (closest to physiologic concentration) 
similarly resulted in reduction in 123I-TGF-P1 binding to the three receptor subtypes, by 
75%, 31%, and 57% for I, II, and betaglycan respectively. 3 mM phenobarbital was the 
only concentration of the drug which produced an increase in binding, by 30%, 56%, and 
60% for I, II, and betaglycan. With the exception of one condition (300 pM phenobarbital 
: Type I receptor), a general trend was observed that as phenobarbital dose increased, 125I- 
I 
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TGF-pi binding to all three receptor types steadily increased from below control levels to 
above. 
In the antibody studies, treatment with 100 nM cortisol for 24 h resulted in only a 10% 
reduction in total cellular Type I receptor protein, while simultaneously leading to a 53% 
increase in total cellular Type II receptor protein (Figs. 8-9). Total cellular betaglycan 
was not assessed as the anti-betaglycan antibody that was available did not react with our 
protein blots. 30 pM phenobarbital resulted in a 29% reduction in total cellular Type I 
receptor protein, and a 14% reduction in Type II receptor protein. 24-h incubation with 3 
mM phenobarbital resulted in a 71% reduction in Type I receptor protein, while causing 
an increase of 42% in Type II receptor protein. Overall, increasing concentrations of 
phenobarbital appeared to cause a progressive decrease in Type I receptor protein 
amounts. Additionally, phenobarbital concentrations increasing from 30 pM to 3mM 
appeared to gradually increase Type II receptor protein amounts; however the effects at 3 
pM did not fit this trend. These results are collected in Table 1. 

TGF-Bl Dose-Response Curve in Rat Dermal Fibroblasts 
(DNA Synthesis) 
FIG. 1: Effect of TGF-Bl on DNA synthesis rates in dermal fibroblast cultures from 
fetal rat scalp. Serum-deprived confluent cell cultures were incubated for 24 h with 
the concentrations of TGF-Bl shown. DNA synthesis was measured by pulse¬ 
labeling with [^Hjthymidine for the last 2 h of culture as described in Materials and 
Methods. Data are the means +/-SE of results of one experiment including six 
replicate culture wells per condition. DNA synthesis was significantly enhanced by 
TGF-Bl concentrations at or below 1.0 ng/ml, with a peak of stimulation at 0.1 ng/ml. 

Response by Rat Dermal Fibroblasts to Phenobarbital 
(DNA synthesis) 
g -TGFB1 Q + TGFB1 (0.1 ng/ml) 
FIG. 2: Effect of phenobarbital and cortisol on DNA synthesis rates in untreated and 
TGF-61-stimuhated dermal fibroblast cultures from fetal rat scalp. Serum-deprived 
confluent cell cultures were incubated for 24 h without or with the concentrations of 
phenobarbital or cortisol shown, followed by a 24-h treatment with 0.1 ng/ml TGF- 
31. DNA synthesis was measured by pulse-labeling with ['H]thymidine for the last 2 
h of culture and analyzed as described in Materials and Methods. Data are the means 
+/-SE of results of one representative experiment including six replicate culture wells 
per condition. Both basal DNA synthesis and the stimulatory effect of 0.1 ng/ml 
TGF-B1 were inhibited by 100 nM cortisol. Phenobarbital had little effect on basal 
DNA synthesis at concentrations of 30 pM and 300 uM, and TGF-Bl tended to 
stimulate to the same extent without or with phenobarbital. DNA synthesis (both +/- 
TGF-Bl) was inhibited by 3 mM phenobarbital. 

Response by Rat Dermal Fibroblasts to Phenobarbital 
(Collagen synthesis) 














































FIG. 3: Effect of phenobarbital and cortisol on collagen synthesis rates in untreated 
and TGF-Bl-stimulated dermal fibroblast cultures from fetal rat scalp. Serum- 
deprived confluent cell cultures were incubated for 24 h without or with the 
concentrations of phenobarbital or cortisol shown, followed by a 24-h treatment with 
10 ng/ml TGF-131. Collagen synthesis was measured by pulse-labeling with 
[’HJproline for the last 2 h of culture and analyzed as described in Materials and 
Methods. Data are the means +/-SE of results of one representative experiment 
including six replicate culture wells per condition. Both basal collagen synthesis and 
the stimulatory effect of 10 ng/ml TGF-131 were inhibited by 100 nM cortisol. 
Phenobarbital had little effect on basal collagen synthesis at concentrations of 3 p.M, 
30 p.M and 300 p.M. 10 ng/ml TGF-131 tended to stimulate to the same extent without 
or with phenobarbital. Collagen synthesis (both +/-TGF-I31) was inhibited by 3 mM 
phenobarbital. 

Response by Rat Dermal Fibroblasts to Phenobarbital 
(Non-collagen protein synthesis) 
□ -TGF131 [J + TGFB1 (10 ng/ml) 
Q_ 
FIG. 4: Effect of phenobarbital and cortisol on non-collagen protein synthesis rates 
in untreated and TGF-B 1-stimulated dermal fibroblast cultures from fetal rat scalp. 
Cells were prepared and treated as described for Fig. 3, and non-collagen protein 
synthesis was measured by pulse-labeling with [’Hjproline for the last 2 h of culture 
and analyzed as described in Materials and Methods. Data are the means +/-SE of 
results of one representative experiment including six replicate culture wells per 
condition. This experiment was carried out simultaneously and using the same 
original cell cultures as for the experiment depicit in Fig.3. As with collagen 
synthesis, both basal non-collagen synthesis and the stimulatory effect of 10 ng/ml 
TGF-61 were inhibited by 100 nM cortisol. Phenobarbital had little effect on basal 
non-collagen synthesis at concentrations of 3 pM, 30 pM and 300 pM. 10 ng/ml 
TGF-B1 tended to stimulate to the same extent without or with phenobarbital. Non¬ 
collagen protein synthesis (both +/-TGF-B1) was inhibited by 3 mM phenobarbital. 
' 
12T-TGFft: Type I Receptor Binding in Rat Dermal 












FIG. 5: Effect of cortisol and phenobarbital on TGF-61 binding in dermal fibroblast 
cultures from fetal rat scalp. Serum-deprived confluent cultures were incubated for 
24 h without or with 100 nM cortisol or 30 uM to 3 mM phenobarbital, rinsed, and 
labeled for 3 h at 4QC with 80 pM I25I-TGF-I31. The cultures were rinsed, cross-linked 
with disuccinimidyl suberate, and fractionated by electrophoresis through a 5-10% 
polyacrylamide gel, and '"'l-labeled binding complexes were displayed by 
autoradiography as described in Materials and Methods. Complexes were designated 
by analogy to other tissue systems, in which the betaglycan complex migrates at 
>200kDa, the type II complex at 70 kDa, and the type I complex at 53 kDa, identified 
relative to a mixture of protein standards. Densitometric analysis of bands was used 
to quantify I251-TGF-G1 binding to the three receptor subtypes: type 1 (Fig. 5), type II 
(Fig. 6), and betaglycan (Fig. 7) for the various conditions labeled. Data displayed in 
all three figures are results from one experiment including six replicate culture wells 
per condition. Binding to the type I receptor was inhibited by cortisol exposure and 
by 3 pM to 300 pM phenobarbital, while 3mM phenobarbital resulted in increased 
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l2T-TGFB : Type II Receptor Binding in Rat Dermal 
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FIG. 6: (See Fig. 5 legend for details) Binding to the TGFB type 11 receptor was 
inhibited by cortisol exposure and by 3 uM and 30 uM phenobarbital, while 3mM 
phenobarbital resulted in increased '"’I-TGF-B 1 binding. Exposure to 300 uM 
phenobarbital resulted in similar binding levels as found in untreated cells. Equal 



















12SI-TGFfi : Betaglycan (Type III Receptor) Binding in Rat Dermal 
Fibroblasts after Phenobarbital Exposure 
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FIG. 7: (S ee Fig. 5 legend for details) Binding to betaglycan was inhibited by 
cortisol exposure and by 3 uM and 30 uM phenobarbital, while 3mM phenobarbital 
resulted in increased '“VTGF-Bl binding. Exposure to 300 liM phenobarbital 
resulted in similar binding levels as found in untreated cells. Equal amounts of 
protein (100 ng) were loaded in each lane. 

TGFB Type I Receptor Protein in Rat Dermal Fibroblasts after 
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FIG. 8: Effect of cortisol and phenobarbital on total receptor protein levels in 
dermal fibroblast cultures from fetal rat scalp. Serum-deprived confluent cultures 
were incubated for 24 h without or with 100 nM cortisol or 30 uM to 3mM 
phenobarbital, rinsed, and fractionated by electrophoresis through a 5-10% 
polyacrylamide gel. Individual TGF-B receptor subtypes were detected by probing 
with anti-TGF-6-Receptor specific antibody preparations and were visualized by 
chemiluminescence as described in Materials and Methods. Receptor subtypes were 
designated by analogy to other tissue systems, in which the type II complex migrates 
at 70 kDa, and the type I complex at 53 kDa, identified relative to a mixture of 
protein standards. Densitometric analysis of bands was used to quantify specific 
antibody binding to two receptor subtypes: type 1 (Fig. 8) and type II (Fig. 9), for the 
various conditions labeled. Data displayed in Fig. 8 are results from one experiment 
including six replicate culture wells per condition. Type 1 receptor protein decreased 
after exposure to 30 p.M to 3 mM phenobarbital, while neither cortisol nor 3 uM 
phenobarbital altered amounts of type I receptor appreciably. Equal amounts of 
protein (100 ng) were loaded in each lane. 

TGFft Type II Receptor Protein in Rat Dermal Fibroblasts after 
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FIG. 9: (See Fig. 8 legend for details) Data displayed are averaged results from two 
separate experiments including six replicate culture wells per condition. Cortisol 
exposure resulted in a marked increase in amount of TGFB Type 11 receptor protein 
in this experiment. Type II receptor also appeared to increase at phenobarbital 
concentrations of 3 pM and 3 mM, but remained relatively unchanged from control 
levels at concentrations of 30 and 300 uM. Equal amounts of protein (100 ng) were 




% of Control 
Type II Type III 
Cortisol 10"7M 14% 58% 67% 
Phenobarbital 30 pM 25% 69% 43% 
Phenobarbital 3 mM 130% 156% 160%c 
Antibody Binding 
Type I Type II 
Cortisol 10_7M 90% 153% 
Phenobarbital 30 |iM 71% 86% 
Phenobarbital 3 mM 29% 142% 
TABLE 1: Effect of cortisol or phenobarbital treatment on l2r,I-TGF-[31 
binding to TGF-(3 receptor types I, II and III, and on specific anti-receptor 




The barbiturate phenobarbital has selective anticonvulsant activity, and due to its low 
toxicity, high efficacy, and low cost, is still widely used to treat patients with seizure 
disorders. In a 1989 study, Mattson et al. described a higher incidence of connective 
tissue disorders in patients taking phenobarbital over a year’s time than is present in the 
general population. This association between connective tissue diseases (including 
Dupuytren’s contracture of the palmar fascia, “frozen shoulder,” and Peyronie’s disease or 
penile fibrosis) and phenobarbital intake has thus far not been further investigated. We 
know from review of the literature that the connective tissue diseases mentioned involve 
some component of superfluous extracellular matrix deposition with or without fibroblast 
hyperproliferation (LeRoy 1974; Murrell et al. 1991; Kikuchi et al. 1992; Alioto et al. 
1994). Additionally, we know that TGF-pi is a potent stimulator of extracellular matrix 
(ECM) production in many cell types, including fibroblasts (Centrella et al. 1987; Border 
& Noble 1995). In fact, a clear association has been demonstrated between dysregulation 
of TGF-pi activity and fibrotic processes affecting other human organ systems. It 
therefore seems feasible that altered regulation of TGF-pi activity at some level may 
contribute to pathogenesis of these connective tissue disorders, as further studies have 
suggested (Kloen et al. 1993). 
Given this body of information, we set out to determine if phenobarbital has a direct effect 
on ECM production in and cell proliferation of fibroblasts. Stimulation of one or both of 
' 
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these variables by phenobarbital would indicate a direct causal relationship in the 
development of Dupuytren-like disorders, which would be of clinical interest. Further, we 
asked whether phenobarbital altered the stimulatory effect of TGF-pi toward collagen and 
DNA synthesis in these cells. TGF-pi is one of a group of growth factors central to the 
maintenance of tissue homeostasis in most cell types. Modification, whether suppression 
or enhancement, of the cellular responsiveness to TGF-pi could therefore result in 
physiologically significant outcomes. We chose to culture dermal fibroblasts from fetal rat 
scalp tissue because of their ready availability in our laboratory and excellent proliferative 
capacity. In order to establish the baseline responsiveness of our cells we set up two 
control groups. One group assessed normal fibroblast sensitivity to TGF-pi, in which we 
expected to see stimulation of both collagen and DNA synthesis with TGF-pi treatment as 
demonstrated in previous studies (Kloen et al. 1995). The second control group assessed 
fibroblast response to a concentration of cortisol known to suppress collagen and DNA 
synthesis, as well as the stimulatory effect of TGF-pi, in osteoblasts (Centrella et al. 
1991). 
TGF-pi proved to be stimulatory and cortisol proved to be inhibitory for both collagen 
and DNA synthesis in rat dermal fibroblasts. Therefore, we were able to conclude that our 
cell culture had produced cells sensitive and responsive to stimuli in predictable ways. 
Phenobarbital, when tested at concentrations of 3 to 30 pM had no clear effect on either 
ECM production or cell proliferation. Across all experiments, however, the highest dose 
of phenobarbital (3 mM) inhibited both collagen and DNA synthesis, as well as the 
>» 
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stimulatory effect of TGF-P 1. Clinically, the concentration of phenobarbital in the 
bloodstream of patients receiving the drug is about 10 mg/ml, or 43 pM (MW = 232.24). 
Therefore, the effect of so high a concentration as 3 mM seems unlikely to be 
physiologically significant. It appears then, that under the described conditions, using 
these cells, physiologic levels of phenobarbital do not appear to have a direct effect with 
respect to collagen or DNA synthesis. 
These results point away from our original hypothesis that the Dupuytren-like connective 
tissue diseases may result directly from phenobarbital-induced overproduction of ECM 
proteins. Further, phenobarbital does not appear to alter the fibroblasts’ level of response 
to TGF-P 1. However, it is important to remember that changes in cell behavior related to 
TGF-P 1 may be effected via various mechanisms: one might consider alterations in 
production, secretion, or subsequent activation of latent TGF-(31, changes in TGF-P 
receptor expression, or alterations in post-receptor cell signaling. It was of interest 
therefore to us to evaluate whether TGF-P receptor numbers or receptor affinity for ligand 
changed with phenobarbital exposure. 
Recall that receptor types I and II are transmembrane receptors directly responsible for 
propagating the TGF-P signal to attain the desired cellular effects. Betaglycan exists in 
both soluble and membrane-bound forms, which may correlate to storage and ligand- 
presenting roles, respectively. Therefore, if change in receptor profile were to account for 
increased matrix deposition and resultant fibrosis, we would have expected to see an 

increased ratio of type I and II receptors to betaglycan. This, however, is not what our 
studies showed. Rather, 24-h exposure of dermal fibroblasts to clinically therapeutic 
levels of phenobarbital resulted in a reduction in TGF-P binding to all receptor subtypes. 
Further, the greatest reduction in binding occurred at the type I receptor. By looking at 
the results of 123I-TGF~pi binding alone, it is not possible to determine whether decreased 
binding results from decreased affinity of receptor for ligand, or decreased overall 
availability of receptor on the cell surface. Looking to the results of antibody-binding 
experiments to help clarify this point, we found parallel reductions in both total cellular 
Type I and II receptor proteins after exposure to therapeutic phenobarbital levels as 
compared to untreated samples. This suggests, but does not determine, that overall 
amounts of receptor Types I and II are decreased in cells treated with this concentration of 
phenobarbital. Such a decrease in receptor amount could either result from a decreased 
level of transcription of receptor mRNA or an increase in the rate of receptor protein 
turnover. 
The question arises, why did we not see the results we expected to? There are a number 
of possible explanations. First, further repetition of all experiments (which unfortunately, 
time did not permit) may have led to a more accurate interpretation of the data given a 
greater overall sample size. Worth consideration is that Mattson’s clinical study revealed 
a significant, but only 10% increase in incidence of Dupuytren-like diseases over controls. 
Therefore, it is likely that we would only see a tendency toward increased matrix 
production in 10% of our cells, undetectable in a small sample size. Second, we were 
/ 
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clearly operating under the assumption that fibrotic processes analogous to human 
connective tissue disorders occur in rats, which may be a misguided supposition. I, in fact, 
could find no literature describing fibrotic skin diseases in rats, which may mean human 
fibroblasts would have been necessary to culture in order to accurately demonstrate our 
hypothesis. Third, we modeled our experiments based on a clinical study where patients 
received phenobarbital chronically, over a year’s time. It is quite possible that longer or 
repeated exposure to the drug would be necessary in order to mimic the clinical scenario 
described. Successful demonstration of our hypothesis might even require continued 
passaging of cells while exposing to phenobarbital to select for cultures with the correct 
conditions for study. 
Further possibilities include insufficient amounts of phenobarbital receptors on the surfaces 
of rat dermal fibroblasts to evoke any response. The mechanism of phenobarbital 
effectiveness in the CNS involves action on the GABAa receptor of neurons, resulting in 
potentiation of synaptic inhibition. Its mechanism of action on other tissue types, 
however, is unclear; if, however, it binds with greater efficiency to human fibroblasts than 
those in rats, our inability to see its effects might be explained. Yet another possibility is 
that fibroblasts cultured in exclusion of other cell types may not provide a critical 
intermediary for response to phenobarbital. The development of the connective tissue 
disorders described may in fact be an indirect effect of exposure to this drug, mediated by 
another molecule or other molecules unavailable to our cells in culture. Future studies 
/ 
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might address any one of these issues, and might significantly contribute to the 
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